CARLSBAD, Calif. & EUGENE, Ore.--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ:IVGN - News), a provider of essential life science technologies for research, production and diagnostics, announced today the company will become the exclusive North American distributor of all MitoSciences products, including antibodies and assays used for researching mitochondrial proteins and diseases. MitoSciences currently has the world’s largest collection of anti-mitochondrial monoclonal antibodies and immunoassays.
As existing MitoSciences distribution agreements expire, Invitrogen will take over those agreements worldwide on an exclusive basis. The deal adds more than 200 new products to Invitrogen’s antibody and kit catalog.
“This agreement will allow scientists greater ease of access to the antibodies needed to conduct their research,” said August Sick, vice president and general manager of Invitrogen’s Cellular Analysis Business Unit. “Furthermore, Invitrogen plans to offer more prepackaged kits in the future that combine the MitoSciences technology with our fluorescent labeling and cell separation technologies for mitochondrial disease research. Our partnership with MitoSciences represents another step in Invitrogen’s strategy of investing in high-growth areas, such as cell biology, and maintaining our leadership position as the number one provider of life science tools for research.”
The powerhouse of the cell, mitochondria create more than 90 percent of the energy needed by the body. Diseases of the mitochondria most often damage cells of the brain, heart, liver, muscles and respiratory system causing cardiac disease, respiratory complications, susceptibility to infection and developmental delays. Parkinson's Disease, diabetes, and cancer are all recognized as being at least partially caused by mitochondrial dysfunction.
"MitoSciences is increasingly focused on developing products for drug discovery and in vitro diagnostics," said Jean-Paul Audette, president of MitoSciences, "and with Invitrogen's significant distribution channels plus its expertise in multiplexing assay technologies the relationship provides MitoSciences with not only strong marketing support but also a partner in deploying our technology on new platforms relevant to our applications."
For more information, visit www.invitrogen.com or www.mitosciences.com.
Invitrogen Corporation (NASDAQ:IVGN - News) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007. For more information, visit www.invitrogen.com.
MitoSciences develops monoclonal antibodies and immunoassays for use in understanding mitochondria and metabolism, with applications in life science research, drug discovery, and in vitro diagnostics. Founded in 2004 by Dr. Roderick Capaldi, noted mitochondrial researcher and author of over 200 papers, and Dr. Michael Marusich, founder and director of the University of Oregon's monoclonal antibody facility, MitoSciences is based in Eugene, Oregon. The company currently employs 18 scientists, many of whom have conducted significant doctoral, post-doctoral or other professional work in mitochondria-related fields.
Safe Harbor Statement
Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to; 1) This agreement will allow scientists greater ease of access to the antibodies needed to conduct their research, and 2) Invitrogen plans to offer more prepackaged kits in the future that combine the MitoSciences technology with its fluorescent labeling and cell separation technologies for mitochondrial disease research. Potential risks and uncertainties include, but are not limited to a) This agreement may or may not allow scientists greater ease of access to the antibodies needed to conduct their research and b) Invitrogen may or may not become the premier life science tools company for cell biology research; and the risks that the market will not accept the companies’ products and services, or that the companies will be unsuccessful in their efforts to develop new products and services, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.
Revelle Bailey, 760-268-7482
Jean-Paul Audette, 541-284-1800
Source: Invitrogen Corporation